Grifols (NASDAQ:GRFS) Sees Unusually-High Trading Volume - Should You Buy?

Grifols, S.A. (NASDAQ:GRFS - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 1,499,752 shares were traded during trading, an increase of 43% from the previous session's volume of 1,049,526 shares.The stock last traded at $10.19 and had previously closed at $10.09.

Analyst Ratings Changes

GRFS has been the subject of several recent analyst reports. JPMorgan Chase & Co. upped their price objective on Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a report on Tuesday, June 17th. Wall Street Zen raised Grifols from a "buy" rating to a "strong-buy" rating in a research report on Monday, July 7th.

Grifols Stock Performance

The company has a market capitalization of $6.91 billion, a P/E ratio of 8.59, a P/E/G ratio of 0.35 and a beta of 0.55. The stock's 50-day moving average price is $8.62 and its 200-day moving average price is $7.80. The company has a current ratio of 2.60, a quick ratio of 0.97 and a debt-to-equity ratio of 1.13.

Hedge Funds Weigh In On Grifols

Large investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. boosted its stake in Grifols by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock worth $247,000 after acquiring an additional 1,657 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Grifols during the fourth quarter worth about $91,000. HighTower Advisors LLC increased its stake in shares of Grifols by 28.3% in the fourth quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock valued at $133,000 after buying an additional 3,936 shares during the period. Envestnet Portfolio Solutions Inc. bought a new stake in Grifols in the fourth quarter valued at approximately $77,000. Finally, Corient Private Wealth LLC raised its position in Grifols by 11.0% in the 4th quarter. Corient Private Wealth LLC now owns 50,883 shares of the biotechnology company's stock valued at $379,000 after buying an additional 5,040 shares during the last quarter.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.